Last updated on March 2019

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

Brief description of study

STRATEGIC-1 is a study designed to determine the best sequence of therapy in patients with metastatic colorectal cancer.

Detailed Study Description

This is a phase III study assessing 2 mutli-line therapeutic strategies in patients with unresectable wild-type RAS metastatic colorectal cancer. All the available treatments are being used in each strategy (oxaliplatine, irinotecan, fluoropyrimidines, bevacizumab, cetuximab or panitumumab) but in a different order:

STRATEGY A: FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab vs.

STRATEGY B: OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan.

Clinical Study Identifier: NCT01910610

Find a site near you

Start Over

CHD Vend e

La Roche sur Yon, France
  Connect »

H pital Nord

Marseille, France
  Connect »

Clinique de l'Alliance

Saint Cyr sur Loire, France
  Connect »

H pital Foch

Suresnes, France
  Connect »

H pitaux du L man

Thonon Les Bains, France
  Connect »

Institut de Canc rologie

Villeneuve-d'Ascq, France
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.